Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen And BAKX Will Develop Latter’s BCL-2 Inhibitor

Investigational BKX-001 is an oral small-molecule activator of BAX • Source: Alamy

More from Clinical Trials

More from R&D